Local view for "https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/962"
| Predicate | Value (sorted: default) |
|---|---|
| rdfs:label | |
| rdf:type | |
| ?:Evidence_dose | |
| ?:Evidence_enzyme_system | |
| ?:Evidence_type | |
| ?:Evidence_value |
"0.0000705"
|
| ?:content |
"Absorption: Peak plasma levels of celecoxib occur approximately 3 hrs after an oral dose. Under fasting conditions, both peak plasma levels (Cmax) and area under the curve (AUC) are roughly dose-proportional up to 200 mg BID; at higher doses there are less than proportional increases in Cmax and AUC [see Food Effects]. Absolute bioavailability studies have not been conducted. With multiple dosing, steady-state conditions are reached on or before Day 5. The pharmacokinetic parameters of celecoxib in a group of healthy subjects are shown in Table 3.
Table 3 Summary of Single Dose (200 mg) Disposition Kinetics of
Celecoxib in Healthy Subjects* Mean (%CV) PK Parameter Values
Cmax, ng/mL|Tmax, hr|Effective t1/2, hr|Vss/F, L |CL/F, L/hr
705 (38) |2.8 (37)|11.2 (31) | 429 (34) | 27.7 (28)
*Subjects under fasting conditions (n=36, 19�52 yrs.)
705ng/mL X 1g/10^9ng X 1000mL/1L = 0.0000705g/L"
|
| dc:creator | |
| dc:date |
"09/24/2009 11:06:27"
|
| rdfs:seeAlso |
All properties reside in the graph file:///home/swish/src/ClioPatria/guidelines/dikb.ttl
The resource appears as object in one triple:
{ celecoxib_maximum_concentration_continuous_value, <http://purl.org/swan/1.2/swan-commons#citesAsSupportingEvidence>, evidence_1963 }